Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling

被引:18
作者
Zhu, Andy Z. X. [1 ]
Ho, Ming-Chih David [1 ]
Gemski, Christopher K. [1 ]
Chuang, Bei-Ching [1 ]
Liao, Mingxiang [1 ]
Xia, Cindy Q. [1 ]
机构
[1] Takeda Pharmaceut Int Co, Dept Drug Metab & Pharmacokinet, Drug Safety & Disposit, 35 Lansdowne St, Cambridge, MA 02139 USA
来源
AAPS JOURNAL | 2016年 / 18卷 / 06期
关键词
acid-reducing agents; drug absorption; drug-drug interaction; pH effect; proton-pump inhibitors; PROTON PUMP INHIBITORS; GASTRIC PH; ANTICANCER AGENTS; ABSORPTION; BIOAVAILABILITY; HUMANS; CANINE; RANITIDINE; VIVO; KETOCONAZOLE;
D O I
10.1208/s12248-016-9972-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For many orally administered basic drugs with pH-dependent solubility, concurrent administration with acid-reducing agents (ARAs) can significantly impair their absorption and exposure. In this study, pH-dependent drug-drug interaction (DDI) prediction methods, including in vitro dissolution-permeation chamber (IVDP) and physiologically based pharmacokinetic (PBPK) modeling, were evaluated for their ability to quantitatively predict the clinical DDI observations using 11 drugs with known clinical pH-dependent DDI data. The data generated by IVDP, which consists of a gastrointestinal compartment and a systemic compartment separated by a biomimic membrane, significantly correlated with the clinical DDI observations. The gastrointestinal compartment AUC ratio showed strong correlation with clinical AUC ratio (R=0.72 and P=0.0056), and systemic compartment AUC ratio showed strong correlation with clinical C-max ratio (R=0.91 and P=0.0003). PBPK models were also developed for the 11 test compounds. The simulations showed that the predictions from PBPK model with experimentally measured parameters significantly correlated with the clinical DDI observations. Future studies are needed to evaluate predictability of Z-factor-based PBPK models for pH-dependent DDI. Overall, these data suggested that the severity of pH-dependent DDI can be predicted by in vitro and in silico methods. Proper utilization of these methods before clinical DDI studies could allow adequate anticipation of pH-dependent DDI, which helps with minimizing pharmacokinetic variation in clinical studies and ensuring every patient with life-threatening diseases receives full benefit of the therapy.
引用
收藏
页码:1512 / 1523
页数:12
相关论文
共 48 条
  • [41] US Food and Drug Administration, 2010, ERL TARC PRESCR INF
  • [42] US Food and Drug Administration, 2007, LAP TYK CLIN PHARM B
  • [43] US Food and Drug Administration, 2007, NIL TAS CLIN PHARM B
  • [44] Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy
    van Lunzen, J.
    Liess, H.
    Arasteh, K.
    Walli, R.
    Daut, B.
    Schuermann, D.
    [J]. HIV MEDICINE, 2007, 8 (04) : 220 - 225
  • [45] Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole Monitoring of Intraluminal and Plasma Drug Concentrations
    Walravens, Jeroen
    Brouwers, Joachim
    Spriet, Isabel
    Tack, Jan
    Annaert, Pieter
    Augustijns, Patrick
    [J]. CLINICAL PHARMACOKINETICS, 2011, 50 (11) : 725 - 734
  • [46] The Use of Betaine HCl to Enhance Dasatinib Absorption in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria
    Yago, Marc R.
    Frymoyer, Adam
    Benet, Leslie Z.
    Smelick, Gillian S.
    Frassetto, Lynda A.
    Ding, Xiao
    Dean, Brian
    Salphati, Laurent
    Budha, Nageshwar
    Jin, Jin Y.
    Dresser, Mark J.
    Ware, Joseph A.
    [J]. AAPS JOURNAL, 2014, 16 (06): : 1358 - 1365
  • [47] pH-Dependent Drug-Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development
    Zhang, L.
    Wu, F.
    Lee, S. C.
    Zhao, H.
    Zhang, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (02) : 266 - 277
  • [48] pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs:: Development of a canine model
    Zhou, R
    Moench, P
    Heran, C
    Lu, XJ
    Mathias, N
    Faria, TN
    Wall, DA
    Hussain, MA
    Smith, RL
    Sun, DX
    [J]. PHARMACEUTICAL RESEARCH, 2005, 22 (02) : 188 - 192